We have an established track record of excellence in R&D. Our commitment to innovation and continuous improvement has enabled us to remain at the forefront of pharmaceutical advancements in the CDMO sector. Our R&D teams are dedicated to developing differentiated dosages, enhancing manufacturing processes, and exploring novel therapeutic areas. Our R&D initiatives are aimed at innovation in relation to taste and odour masking, targeted drug release, solubility/dissolution enhancement, reduced excipient burden, permeation enhancement, and stability enhancement, among others. Our focus on R&D has resulted in the development of 208 innovative formulations since the commencement of our operations.

900

+

DCGI Approvals

860

+

FSSAI Approvals

4000

+

Formulations

R&D Centers Overview

Haridwar -1
R&D center for formulations across various dosage forms, including oral solids, liquids, injectables and topicals.
Haridwar -2
R&D centre for drugs and nutraceutical formulation, across dosage forms such as modified-release oral solids, injectables, nasal sprays, gummies, protein powders and oral liquids.
Mumbai
R&D centre for export-oriented branded formulations for regulated and semiregulated countries. Capabilities include tablets, capsules, ophthalmics, lyophilized injectable, sterile products and hormones.
Barwala
R&D centre dedicated to APIs, intermediates and key starting material.

Haridwar -1

Haridwar -2

Mumbai

Barwala

Connect with us for innovative solutions